Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis

Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis

IntroductionGlucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively used to treat obesity in recent years. These novel drugs are effective at reducing body weight and also the risk of major adverse cardiovascular events in individuals with type 2 diabetes. However, the data of its...

Full description

Saved in:
Bibliographic Details
Main Authors: Raveena Kelkar, Nishad A. Barve, Rohan Kelkar, Sanjeev Kharel, Shalmi Khanapurkar, Rukesh Yadav
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
GLP-1 RA
obesity
cardiovascular event
non-diabetic
overweight
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1453297/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1453297/full

Similar Items